spacer
home > pmps > winter 2017 > formulating a plan
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Formulating a Plan

High doses are often necessary to deliver enough of an orally administered drug to the lungs or nasal passages through the bloodstream. As many medicines are now highly potent, delivery by mouth has the potential to cause severe side effects. Combined with this, when products are taken in this way they are easily metabolised, which means that they are not always adequately administered to the nose or lungs, thus limiting the success of the treatment.

In contrast, inhalation formulations enable pharmaceuticals to be delivered directly to the nasal passages or lungs in smaller doses, reducing the risks of both side effects and drug-to-drug interaction. Their growth in popularity can further be attributed to their ability to give the most direct access to a drug target. For example, many inhaled products are steroid drug classes. They can have a harmful impact on growth and hormone balance if taken in large amounts by children and is, therefore, beneficial to deliver a smaller dose to the site of action.

These local therapies offer fast absorption, rapid response and enable a drug to be administered straight to the conducting zone of the lungs. As a result, they work particularly well for conditions such as asthma. Inhalation also represents a very attractive way to deliver drugs to the brain. In the treatment of migraines, for instance, nasal spray drug delivery into the nose can bring fast and effective relief.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Poonam Aliyah Sheth is a Research Scientist specialising in inhalation product development at Recipharm and she holds a PhD in Pharmaceutical Science from the University of Arizona, US. With particular expertise in MDI formulations, dry powder inhalers and nebulised formulations, she has been integral to the development and manufacture of many original and generic products for inhalation drug delivery for global clients, ranging from emerging to large pharmaceutical organisations.

Ramil Menzeleev, PhD, is Director of Recipharm’s Analytical Sciences department. He oversees analytical method development, providing scientific review for client projects while also participating in the design and development of electronic data recording software platforms. A specialist in analytical chemistry, his expertise covers fast, highly sensitive, accurate and high-throughput quantitation method development. He also manages the selection and implementation of IT solutions, including software for business process management, as well as review and approval software for design, validation, implementation and use in Good Manufacturing Practice environments.
spacer
Poonam Aliyah Sheth
spacer
spacer
spacer
Ramil Menzeleev
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement